Cart
sales@molnova.com
Daprodustat
CAS No. 960539-70-2
Daprodustat( GSK-1278863 | GSK 1278863 )
Catalog No. M16862 CAS No. 960539-70-2
A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 71 | In Stock |
|
| 5MG | 109 | In Stock |
|
| 10MG | 166 | In Stock |
|
| 25MG | 367 | In Stock |
|
| 50MG | 529 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDaprodustat
-
NoteResearch use only, not for human use.
-
Brief DescriptionA nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects.
-
DescriptionA nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease.Anemia Phase 3 Clinical(In Vitro):GSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.
-
In VitroGSK1278863 is an orally administered small-molecule PHI, and stimulates endogenous EPO synthesis and induce effective erythropoiesis. GSK1278863 has been shown to increase erythropoietin levels, leading to increases in hemoglobin, hematocrit and red blood cell numbers.
-
In Vivo——
-
SynonymsGSK-1278863 | GSK 1278863
-
PathwayAngiogenesis
-
TargetHIF/HIF Prolyl-hydroxylase
-
RecptorHIF-PH
-
Research AreaOther Indications
-
IndicationAnemia
Chemical Information
-
CAS Number960539-70-2
-
Formula Weight393.4342
-
Molecular FormulaC19H27N3O6
-
Purity>98% (HPLC)
-
SolubilityDMSO: < 6.8 mg/mL
-
SMILESO=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C3CCCCC3)C1=O)=O)=O
-
Chemical NameGlycine, N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brigandi RA, et al. Am J Kidney Dis. 2016 Jun;67(6):861-71.
2. Hara K, et al. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
3. Johnson BM, et al. Clin Pharmacol Drug Dev. 2014 Mar;3(2):109-17.
molnova catalog
related products
-
SYP-5
A novel potent HIF-1 inhibitor that inhibits hypoxia-induced upregulation of HIF-1.
-
Izilendustat
Tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate inhibit of human recombinant EGLN-1 as substrate after 20 mins by mass spectrophotometric analysis.
-
TAT-cyclo-CLLFVY
Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
